News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
The Power of Pennovation Works: Research and Development
In November, in recognition of the 5th year anniversary of Pennovation Works, the Pennovation Center hosted The Power of Pennovation Works: Research and Development panel.
Philadelphia Ranks Second in New Study Comparing U.S. Cell and Gene Therapy Hubs
Philadelphia ranks second in a newly released study comparing 14 U.S. cell and gene therapy hubs in five key categories.
Penn Spinout Verismo Therapeutics Receives FDA Clearance of Investigational New Drug Application for SynKIR-110™, a KIR-CAR T Cell Immunotherapy Candidate
Verismo plans to begin enrolling patients in the first quarter of 2023 at the initial clinical site, the Hospital of the University of Pennsylvania.
Penn Ranks Number 15 on Report of Top 100 Worldwide Universities Granted U.S. Utility Patents in 2021
The National Academy of Inventors & the Intellectual Property Owners Association ranked Penn in the Top 100 Worldwide Universities Granted U.S. Utility Patents in 2021.
Weissman Lab is Working on New Type of Vaccines to Protect Against All Coronaviruses
The Weissman Lab is working towards developing vaccines that not only target multiple COVID variants, but also multiple types of coronaviruses.
PCI Fellows Enjoy First In-Person Meeting of the Year
On September 19, the PCI Fellows got together for their first in-person meeting since the cohort began in April.
Team of Leading Scientists unite to launch Capstan Therapeutics
Penn spinout Capstan Therapeutics unites decades of combined experience in groundbreaking CAR therapies with the latest advances in mRNA delivery technology to find new cures for cancer and other dise
Innervace Secures Up to $40 Million to Advance Novel Regenerative Medicine Platform for Neurological Disorders
Innervace, a regenerative medicine startup cofounded by Penn Medicine’s Kacy Cullen, PhD, and Douglas Smith, PhD raised up to $40 million in Series A financing.
iECURE Gets Early FDA Designation
The company was awarded FDA orphan drug designation for its experimental therapy, GTP-506, on the heels of the drug receiving rare pediatric disease designation.
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
The combined company, which is expected to operate under the name Carisma Therapeutics Inc., will focus on advancing Carisma’s proprietary cell therapy platform.